The new drug, from drugmakers Sanofi and Provention Bio, works by preventing the body’s immune system from mistakenly attacking cells in the pancreas that make insulin.The FDA said its approval was based on a phase 2 clinical trial of 76 participants who were randomly assigned to receive the drug or a placebo once daily intravenously for 14 days.People in the trial had an early form of Type 1 diabetes in which blood sugar levels are abnormal but symptoms haven't yet developed.People with Type 1 diabetes usually need multiple injections of insulin every day for the rest of their lives, often a great financial burden.“The immeasurable benefits of improved quality of life will be felt not only by those diagnosed with T1D, but also by their families.”Tzield will cost $193,900 for a 14-day supply or $13,850 for a single vial, Kaelan Hollon, a spokesperson for Provention Bio, told NBC News in an email."